Sugammadex improves muscle function after standard neuromuscular recovery (SIMAR) [Verbesserung der Muskelfunktion durch Sugammadex nach normaler neuromuskulärer Erholung] - SIMAR

Technische Universität München0 个研究点目标入组 0 人开始时间: 2010年3月11日最近更新: 2022年4月4日

适应症

试验速览

暂无简介。

•1. ASA I to III
•2. patients between 18-65 years old
•3. patients where general anesthesia with endotracheal intubation with rocuronium is planned
•4. patients who signed confirmed consent for this study
•5. patients who get the study medication within 15 minutes after reaching TOF 0.9
•6. patients who understand german sufficiently
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. known or assumed neuromuscular disease
•2. significant hepatic or renal dysfunction
•3. known or assumed history or family history of malignand hyperthermia
•4. known or assumed allergy against sugammadex, anestehtics, muscle relaxans or other medication used for
•general anesthesia
•5. intake of any medication which interacts with sugammadex
•6. patients which have been in another clinical study in the past 30 days
•7. patiens who are supervised in medical decisions
•8. patient who have contraindications for sugammadex
•9. pregnant females
•10. females who are breast feeding

发起方